Markets Edge — Capital flows, CMO moves, M&A

ISABELLA'S ISLAY M&A Intelligence Oct 9, 11:01 AM EDT

McKesson & Clayton Dubilier & Rice

McKesson and CD&R take Option Care private for $5.8B

Drug distributor McKesson and private equity firm Clayton Dubilier & Rice agreed to take infusion therapy provider Option Care private in a $5.8 billion transaction.

ReadingPE has confirmed healthcare services are now consolidation targets, not growth bets. Margins compress for operators outside the combine.

WatchCD&R's next announcement will be in home health or dialysis. The pattern is already written.

Read full analysis → Original ↗

m&ahealthcareprivate equityconsolidation

HENRI IV Capital Markets Oct 9, 11:01 AM EDT

xAI, Intel, Hugging Face

MSN / Reuters ↗

PE exit market hit $227B as deal volume fell 17% year-over-year

Global private equity and venture capital-backed companies completed exits in a $227 billion market despite a 17% drop in deal volume.

ReadingMid-market PE returns are now contingent on finding the right strategic buyer, not the most aggressive one. Auction processes are contracting.

WatchNext quarter's data. If volume falls another 15%, the definition of a viable exit shifts.

Read full analysis → Original ↗

private equityexitscapital marketsdeal volume

MACALLAN 1926 M&A Intelligence Oct 9, 11:01 AM EDT

GTCR & Tactacam

WSJ Private Equity ↗

GTCR acquired PE-backed Tactacam for over $1B

GTCR completed the acquisition of Tactacam, a previously private-equity-backed action camera maker, in a transaction valued above $1 billion.

ReadingHardware entrepreneurs calling themselves platforms need to understand they are now shopping for a sponsor's playbook, not capital.

WatchGTCR's integration plan. If they consolidate Tactacam with another portfolio company, the category is narrowing.

Read full analysis → Original ↗

m&aprivate equityhardwaresecondary

LOUIS XIII Venture Intelligence Oct 9, 11:01 AM EDT

TRexBio & Retension Pharmaceuticals

PharmExec ↗

TRexBio and Retension priced IPOs, raised $161.7M combined

TRexBio and Retension Pharmaceuticals priced their initial public offerings, raising a combined $161.7 million to fund their immunology and hypertension pipelines before their NASDAQ debuts.

ReadingThe biotech IPO window remains real but shrinking. Timing now matters more than narrative.

WatchTheir first earnings calls. If either shows pipeline acceleration, the next cohort reprices upward.

Read full analysis → Original ↗

ipobiotechcapital marketsfunding

PAPPY 23 M&A Intelligence Oct 9, 11:01 AM EDT

Bain Capital Private Equity

MarketScreener ↗

Bain Capital acquired 9.75% stake in Baudroie for ¥9.3B

Bain Capital Private Equity completed the acquisition of a 9.75% stake in Baudroie, Inc. (TSE:4413) for ¥9.3 billion, signaling PE interest in Japanese mid-market operators.

ReadingMinority stakes are now positioning moves for PE, not passive investments. Watch for the follow-on announcement.

WatchWhether Bain files a Schedule 13D or moves toward control. The first filing tells you everything about the next two years.

Read full analysis → Original ↗

private equityjapanminority stakestrategic

JOHNNIE BLUE Global Business News Oct 9, 11:01 AM EDT

Kakao (Korea)

MSN ↗

Kakao's spin-off plan faces shareholder opposition, stock declines

Kakao announced a spin-off plan designed to increase corporate value, but the proposal has faced growing controversy and the stock price has fallen in response.

ReadingAsian conglomerates calling for strategic splits now need to prove the math, not just the theory. Shareholders are no longer patient with process.

WatchWhether Kakao revises the plan or doubles down. The next earnings call will be the inflection.

Read full analysis → Original ↗

koreacorporate strategyshareholder tension

WELL POUR Venture Intelligence Oct 9, 11:01 AM EDT

Oura Health

Seeking Alpha ↗

Oura postponed its $2.1B IPO citing market conditions

Smart ring maker Oura postponed its $2.1 billion IPO, which was scheduled to debut this week, citing unfavorable market conditions.

ReadingHardware IPO calendars are now backward: announce the move first, then price. The earlier model is dead.

WatchWhether Oura files a revised S-1 within 90 days or falls silent for two quarters.

Read full analysis → Original ↗

ipohardwarepostponementmarket conditions